Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on X about a recent paper he co-authored with colleagues published in Cancer Treatment Reviews:
“Do ADCs work when used in sequence?
We systematically reviewed 23 studies, finding that: it depends! Relevant cross-resistance is seen if two TOPO1 ADCs are sequenced (irrespective of target).Less cross-resistance is seen if switching payload class.”
Jordyn Silverstein, Hematology/Oncology Chief Fellow at UCLA, shared this post, adding:
“Here in gynecologic oncology we have a lot to learn from our breast colleagues particularly with multiple ADCs approved and many in trials- thanks for this helpful article!”
Title: Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
Authors: Luiz F. Costa de Almeida, Luís Felipe Leite, Anelise Poluboiarinov Cappellaro, Lucas Diniz da Conceição, Mariana Macambira Noronha, Jessé Lopes da Silva, Andreia Cristina de Melo, Felipe Batalini, Paolo Tarantino
Read the Full Article in Cancer Treatment Reviews.
More posts featuring Paolo Tarantino on OncoDaily.